Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Pharmacogenetics|February 4, 2003
The Gln27Glu beta2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivoHeike Bruck, Kirsten Leineweber, Rainer Büscher, et al.Kidney International|October 4, 2013
The prevalence, severity, and association with HbA1c and fibrinogen of cognitive impairment in chronic kidney diseaseUlla K Seidel, Janine Gronewold, Michaela Volsek, et al.Plos One|March 12, 2014
Physical, cognitive and emotional factors contributing to quality of life, functional health and participation in community dwelling in chronic kidney diseaseUlla K Seidel, Janine Gronewold, Michaela Volsek, et al.Plos One|November 12, 2016
Cognitive Performance Is Highly Stable over a 2-Year-Follow-Up in Chronic Kidney Disease Patients in a Dedicated Medical EnvironmentJanine Gronewold, Olga Todica, Ulla K Seidel, et al.Journal of the American Society of Nephrology : JASN|January 16, 2009
Avosentan reduces albumin excretion in diabetics with macroalbuminuriaRené R Wenzel, Thomas Littke, Susan Kuranoff, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|November 5, 2004
Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo studyHeike Bruck, Ulrike Poller, Hendrik Lüssenhop, et al.Pacing and Clinical Electrophysiology : PACE|July 29, 2010
Iterative cardiac output measurement for optimizing cardiac resynchronization therapy: a randomized, blinded, crossover studyNico Reinsch, Thomas Konorza, Dagmar Woydowski, et al.Kidney & Blood Pressure Research|December 21, 2013
Associations of smoking with alterations in renal hemodynamics may depend on sex--investigations in potential kidney donorsHana Guberina, Marcus Baumann, Heike Bruck, et al.Journal of the American College of Cardiology|October 24, 2002
Age-dependent changes of cardiac neuronal noradrenaline reuptake transporter (uptake1) in the human heartKirsten Leineweber, Thekla Wangemann, Christine Giessler, et al.British Journal of Clinical Pharmacology|November 3, 2010
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorDagmar Kubitza, Michael Becka, Wolfgang Mueck, et al.Pageof 3